Regression of existing glomerulosclerosis by inhibition of aldosterone

Journal of the American Society of Nephrology

Volumn 16, Issue 11, 2005, Pages 3306-3314

  Aldigier, Jean Claude ^a   Kanjanbuch, Talerngsak ^a   Ma, Li Jun ^a   Brown, Nancy J ^a   Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; HYDRALAZINE PLUS HYDROCHLOROTHIAZIDE PLUS RESERPINE; HYDROCHLOROTHIAZIDE; LOSARTAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; GLOMERULOSCLEROSIS; HORMONE INHIBITION; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; MONOTHERAPY; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; REMISSION; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; GLOMERULONEPHRITIS; KIDNEY FUNCTION TEST; PATHOLOGY; PROTEINURIA; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DIURETICS; GLOMERULONEPHRITIS; KIDNEY FUNCTION TESTS; LOSARTAN; MALE; NEPHRECTOMY; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; SPIRONOLACTONE; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 31544448314     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004090804     Document Type: Article

References (56)

1. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1996
2. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90: 766-771, 1992
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
4. Brenner B, Cooper M, de Zeeuw D: Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
6. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352: 1252-1256, 1998
7. Ma LJ, Fogo AB: Role of angiotensin II in glomerular injury. Semin Nephrol 21: 544-553, 2001
8. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063-1068, 1996
9. Hostetter TH, Kren S, Ibrahim HN: Mineralocorticoid receptor blockade in the remnant kidney model [Abstract]. J Am Soc Nephrol 10: 75, 1999
10. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CTJ: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451-458, 1998
11. Brown NJ, Nakamura S, Ma LJ, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB: Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219-1227, 2000
12. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB: Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 38: 2425-2436, 2000
13. Remuzzi A, Gagliardini E, Donadoni C, Fassi A, Sangalli F, Lepre MS, Remuzzi G, Benigni A: Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 62: 885-894, 2002
14. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75, 1998
15. Ma L-J, Nakamura S, Nakamura I, Marcantoni C, Fogo AB: High dose angiotensin II type 1 receptor antagonist (AT1RA) and angiotensin converting enzyme inhibitor (ACEI) in regression of glomerulosclerosis [Abstract]. J Am Soc Nephrol 13: 342, 2002
16. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB: Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59: 1899-1910, 2001
17. Fogo AB: Progression and potential regression of glomer-ulosclerosis. Kidney Int 59: 804-819, 2001
18. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 34: 709-717, 1999
19. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003
20. Hene RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 21: 98-101, 1982
21. Chrysostomou A, Becker G: Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal diseases. N Engl J Med 345: 925-928, 2001
22. Sato A, Saruta T: Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 18: 781-788, 2003
23. Ruilope LM, Miranda B, Morales JM, Rodicio JL, Romero JC, Raij L: Converting enzyme inhibition in chronic renal failure. Am J Kidney Dis 13: 120-126, 1989
24. Young M, Funder J: The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 271: E883-E888, 1996
25. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237, 1999
26. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK: Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871-3878, 2000
27. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, Garcia-Torres R, Lopez-Casillas F, Gamba G, Bobadilla Na: Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63: 43-52, 2003
28. Wang W, McClain JM, Zucker IH: Aldosterone reduces baroreceptor discharge in the dog. Hypertension 19: 270-277, 1992
29. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K: Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1beta. Eur J Pharmacol 290: 69-73, 1995
30. Jazayeri A, Meyer WJ 3rd: Mineralocorticoid-induced increase in beta-adrenergic receptors of cultured rat arterial smooth muscle cell. J Steroid Biochem 33: 987-991, 1989
31. Ulian ME, Schelling Jr, Linas SL: Aldosterone enhances angiotensin II receptor binding and inositol phosphate response. Hypertension 20: 67-73, 1992
32. Ngarmukos C, Grekin RJ: Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab 281: E1122-E1127, 2001
33. Le Moellic C, Ouvrard-Pascaud A, Capurro C, Cluzeaud F, Fay M, Jaisser F, Farman N, Blot-Chabaud M: Early non-genomic events in aldosterone action in renal collecting duct cells: PKCalpha activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J Am Soc Nephrol 15: 1145-1160, 2004
34. Brilla CG, Weber KT: Mineralocorticoid excess, dietary medium and myocardial fibrosis. J Lab Clin Med 120: 893-901, 1992
35. Bidani AK, Griffin KA, Bakris G, Picken MM: Lack of evidence of blood-pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 57: 1651-1661, 2000
36. Yoshioka T, Shiraga H, Yoshida Y, Fogo A, Glick AD, Deen WM, Hoyer JR, Ichikawa I: "Intact nephrons" as the primary origin of proteinuria in chronic renal disease. Study in the rat model of subtotal nephrectomy. J Clin Invest 82: 1614-1623, 1988
37. Fogo AB, Yoshida Y, Glick AD, Homma T, Ichikawa I: Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 82: 322-333, 1988
38. Yoshida Y, Fogo AB, Ichikawa I: Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 35: 654-660, 1989
39. Ketteler M, Noble NA, Border WA: Transforming growth factor-beta and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 57: 279-295, 1995
40. Bottenger EP, Bitzer M: Transforming growth factor-beta signaling in renal disease. J Am Soc Nephrol 13: 2600-2610, 2002
41. Sun Y, Zhang J, Zhang JQ, Ramires FJ: Local angiotensin II and transforming growth factor-beta 1 in renal fibrosis of rats. Hypertension 35: 1078-1084, 2000
42. Juknevicius I, Segal Y, Kren S: Aldosterone causes TGF-beta expression [Abstract]. J Am Soc Neprol 11: 622A, 2000
43. Eddy AA: Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 283: F209-F220, 2002
44. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA: A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112: 379-388, 2003
45. Nakamura S, Nakamura I, Ma LJ, Vaughan DE, Fogo A: Plasminogen activator inhibitor-1 (PAI-1) expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58: 251-259, 2000
46. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994
47. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 51: 664-671, 1997
48. van Zonneveld AJ, Curriden SA, Loskutoff DJ: Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A 85: 5525-5529, 1988
49. Eren M, Vaughan DE: Angiotensin II and angiotensin IV induce PAI-1 expression through a shared promoter element [Abstract]. Circulation 98: 1994, 1998
50. Brown NJ, Agirbasli Ma, Williams GH, Lichfield WR, Vaughan DE: Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans. Hypertension 32: 965-971, 1998
51. Hatakeyama H, Miramori I, Fujita T, Takeda Y, Takeda R, Yamamoto H: Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269: 24316-24320, 1994
52. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ: Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 87: 448-452, 2002
53. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273: 4883-4891, 1998
54. Lottermoser K, Hertfelder H-J, Vetter H, Dusing R: Fibrinolytic function in diuretic-induced volume depletion. Am J Hypertens 13: 359-363, 2000
55. Benstein JA, Feiner HD, Parker M, Dworkin LD: Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. Am J Physiol 258: F1675-F1681, 1990
56. ALLHAT officers and coordinators for the ALLHAT collaborative research group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288: 2981-2997, 2002